The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Psoriasis is a frequent chronic inflammatory skin disease, nowadays considered a major global health problem. Several new drugs, targeting the IL-23/IL-17A pathway, have been recently licensed or are in clinical development. These therapies represent a major improvement of the way in which psoriasis...
Main Authors: | Nicolo Costantino Brembilla, Luisa Senra, Wolf-Henning Boehncke |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01682/full |
Similar Items
-
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
by: Esther von Stebut, et al.
Published: (2020-01-01) -
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01) -
Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
by: Hélène Bugaut, et al.
Published: (2021-02-01) -
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
by: Silvia Vidal, et al.
Published: (2021-06-01) -
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
by: Taoming Liu, et al.
Published: (2020-11-01)